Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
NZ780173B2 - Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains - Google Patents
[go: Go Back, main page]

NZ780173B2 - Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains - Google Patents

Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

Info

Publication number
NZ780173B2
NZ780173B2 NZ780173A NZ78017312A NZ780173B2 NZ 780173 B2 NZ780173 B2 NZ 780173B2 NZ 780173 A NZ780173 A NZ 780173A NZ 78017312 A NZ78017312 A NZ 78017312A NZ 780173 B2 NZ780173 B2 NZ 780173B2
Authority
NZ
New Zealand
Prior art keywords
isv
multiparatopic
biparatopic
multispecific
bispecific
Prior art date
Application number
NZ780173A
Other versions
NZ780173A (en
Inventor
Judith Baumeister
Marie Paule Lucienne Armanda Bouche
Carlo Boutton
Marie Ange Buyse
Veerle Snoeck
Stephanie Staelens
Original Assignee
Ablynx Nv
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Priority to NZ809551A priority Critical patent/NZ809551A/en
Publication of NZ780173A publication Critical patent/NZ780173A/en
Publication of NZ780173B2 publication Critical patent/NZ780173B2/en

Links

Abstract

Provided are bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic immunoglobulin single variable domain (ISV) constructs comprising an ISV at their C-terminal end, wherein said ISV has the sequence VTVSS(X)n at its C-terminus, wherein n = 1 to 10 and X represents alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

Claims (9)

1. Bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct with an ISV at its C-terminal end, wherein said ISV construct has the sequence VTVSS(X)n at its C-terminus, wherein n = 1 to 10 and each X is an amino acid residue that is independently chosen from alanine (A), glycine (G), valine (V), leucine (L) or isoleucine
2. Bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct according to claim 1, wherein the ISV at the C-terminal end has been modified by introducing one or more amino acid substitutions, additions or deletions in the C- terminal region comprising the C-terminal sequence VTVSS (SEQ ID NO:33) and the amino acid residues at positions 11, 13, 14, 15, 82, 82a, 82b, 83, 84, 107 and 108, wherein the amino acid residues are numbered according to Kabat.
3. Bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct according to claim 2, wherein the ISV at the C-terminal end has been modified by introducing one or more amino acid substitutions, additions in the C-terminal region.
4. Bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct according to any of claims 1 to 3, that has a substantially reduced tendency (such as at least a statistically relevant reduced tendency) to give rise to protein interference, compared to the same ISV construct but without the modifications.
5. Bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct according to any of claims 1 to 4, that has, in the assay described in Example 3, substantially reduced ability to be bound by the polyclonal antibody described in Example 2, compared to the same ISV construct but without the modifications.
6. Bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct according to any of claims 1 to 5, that has, in the assay described in Example 5, substantially reduced ability to be bound by the polyclonal antibody described in Example 2, compared to the same ISV construct but without the modifications.
7. Bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct according to any of claims 1 to 6, wherein each ISV is a humanized VHH or a camelized VH, such as a camelized human VH.
8. Bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct according to any of claims 1 to 7, that comprise a serum albumin-binding peptide or binding domain.
9. Pharmaceutical composition that comprises a bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct according to any of claims 1 to 8 and at least one suitable carrier, diluent or excipient.
NZ780173A 2011-06-23 2012-06-25 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains NZ780173B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ809551A NZ809551A (en) 2011-06-23 2012-06-25 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

Publications (2)

Publication Number Publication Date
NZ780173A NZ780173A (en) 2025-01-31
NZ780173B2 true NZ780173B2 (en) 2025-05-01

Family

ID=

Similar Documents

Publication Publication Date Title
HRP20210739T1 (en) Antigen binding molecules comprising a tnf family ligand trimer
IL295534A (en) Enhanced immunoglobulin variable sites
EP2987806A3 (en) Modified single variable domain antibodies with reduced binding to anti-drug-antibodies
IL259927B2 (en) Humanized anti-cd73 antibodies
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
RU2012111708A (en) HUMANIZED ANTIBODIES TO CDCP1
SG194707A1 (en) Amino acid sequence presenting fusion polypeptide and its use
RU2018102606A (en) MOLECULES RELATING TO PSL PSEUDOMONAS AND WAYS OF THEIR APPLICATION
WO2013087857A3 (en) Antibodies against c. difficile toxins
RU2015126663A (en) HUMANIZED ANTIBODY AGAINST HMGB1 OR ANTIGEN-BINDING Fragment of the INDICATED ANTIBODY
NZ780173A (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
NZ780173B2 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
RU2023116046A (en) METHODS FOR PREDICTING, DETECTING AND REDUCING NON-SPECIFIC PROTEIN INTERFERENCE IN ANALYSIS METHODS USING SINGLE VARIABLE DOMAINS OF IMMUNOGLOBULINS
NZ763845A (en) Improved immunoglobulin variable domains
NZ763848B2 (en) Improved immunoglobulin variable domains
RU2018119966A (en) METHODS OF PREDICTION, DETECTION AND REDUCTION OF NON-SPECIFIC INTERFERENCE OF PROTEINS IN METHODS OF ANALYSIS USING SINGLE VARIABLE DOMAINS OF IMMUNOGLOBULINS
NZ763845B2 (en) Improved immunoglobulin variable domains
NZ731297A (en) Cd3 binding polypeptides
NZ743471B2 (en) Improved immunoglobulin variable domains
NZ763852B2 (en) Improved immunoglobulin variable domains
NZ763850B2 (en) Improved immunoglobulin variable domains
NZ766849A (en) Compound targeting il-23a and tnf-alpha and uses thereof
NZ766849B2 (en) Compound targeting il-23a and tnf-alpha and uses thereof
NZ726448B2 (en) Improved immunoglobulin variable domains
RU2024118294A (en) METHODS FOR PREDICTION, DETECTION AND REDUCTION OF NON-SPECIFIC PROTEIN INTERFERENCE IN ANALYSIS METHODS USING SINGLE VARIABLE DOMAINS OF IMMUNOGLOBULINS